Nial J.
Wheate‡
,
Damian P.
Buck
,
Anthony I.
Day
and
J. Grant
Collins
*
School of Physical, Environmental and Mathematical Sciences, University College, University of New South Wales, Australian Defence Force Academy, Canberra, ACT 2600, Australia. E-mail: g-collins@adfa.edu.au; Fax: +61 (02) 6268 8002
First published on 28th November 2005
The encapsulation of cisplatin by cucurbit[7]uril (Q[7]) and multinuclear platinum complexes linked via a 4,4′-dipyrazolylmethane (dpzm) ligand by Q[7] and cucurbit[8]uril (Q[8]) has been studied by NMR spectroscopy and molecular modelling. The NMR studies suggest that some cisplatin binds in the cucurbituril cavity, while cis-[PtCl(NH3)2(H2O)]+ only binds at the portals. Alternatively, the dpzm-linked multinuclear platinum complexes are quantitatively encapsulated within the cavities of both Q[7] and Q[8]. Upon encapsulation, the non-exchangeable proton resonances of the multinuclear platinum complexes show significant upfield shifts in 1H NMR spectra. The H3/H3* resonances shift upfield by 0.08 to 0.55 ppm, the H5/H5* shift by 0.9 to 1.6 ppm, while the methylene resonances shift by 0.74 to 0.88 ppm. The size of the resonance shift is dependent on the cavity size of the encapsulating cucurbituril, with Q[7] encapsulation producing larger shifts than Q[8]. The upfield shifts of the dpzm resonances observed upon cucurbituril encapsulation indicate that the Q[7] or Q[8] is positioned directly over the dpzm linking ligand. The terminal platinum groups of trans-[{PtCl(NH3)2}2μ-dpzm]2+ (di-Pt) and trans-[trans-{PtCl(NH3)2}2-trans-{Pt(dpzm)2(NH3)2}]4+ (tri-Pt) provide a barrier to the on and off movement of cucurbituril, resulting in binding kinetics that are slow on the NMR timescale for the metal complex. Although the dpzm ligand has relatively few rotamers, encapsulation by the larger Q[8] resulted in a more compact di-Pt conformation with each platinum centre retracted further into each Q[8] portal. Encapsulation of the hydrolysed forms of di-Pt and tri-Pt is considerably slower than for the corresponding Cl forms, presumably due to the high-energy cost of passing the +2 platinum centres through the cucurbituril portals. The results of this study suggest that cucurbiturils could be suitable hosts for the pharmacological delivery of multinuclear platinum complexes.
Much of the synthetic research over the last 20 years has focused on drugs that are able to overcome both resistance and the dose-limiting side-effects.5–9 This has led to the approval of carboplatin and oxaliplatin for clinical use,3 and the development of multinuclear platinum complexes.10–18
Multinuclear platinum complexes are thought to overcome resistance through novel DNA binding modes.14–19 Whereas cisplatin and carboplatin mostly form rigid, short-range intrastrand DNA adducts, the multinuclear complexes are generally identified as forming flexible, long-range interstrand adducts.14–19 In addition, these complexes are taken up by cells to a greater extent than cisplatin.20–29 Particularly important features of multinuclear platinum drugs are their ability to overcome both natural and acquired resistance and show activity in cancers that are defined as p53-mutant.30–33
One such complex, BBR3464 (Fig. 1) has entered phase II clinical trials and three other complexes, BBR3571, BBR3610 and BBR3611 have shown strong clinical potential.3,17,34–38 While these complexes are active at concentrations 10- to 100-fold lower than cisplatin, they are also more toxic. From phase I trials the maximum tolerated dose of BBR3464 was found to be between 0.9 and 1.1 mg m−2, while other BBR complexes appear to be even more toxic.35–38 Recent trials have also shown that these complexes may be degraded (and hence deactivated) by plasma proteins before they reach their intracellular target; possibly explaining the low activity of BBR3464 in phase II trials to date.35–38
![]() | ||
Fig. 1 (A) Structure of cisplatin and a generic multinuclear platinum complex with a range of linking ligands that yield: BBR3463; di-Pt and tri-Pt and (B) cucurbit[n]uril. |
Recently, our group has identified a mechanism by which both the toxicity of these drugs could be decreased, and their degradation reduced within the human body.39 Cucurbit[n]uril (Q[n]) is a barrel-shaped molecule, containing a hydrophobic cavity, formed by the acid catalysed condensation of glycoluril and formaldehyde (Fig. 1).40–44 Cucurbit[n]urils can be synthesised in a variety of sizes (n = 5, 6, 7, 8 and 10), and are capable of encapsulating smaller molecules within their cavities.45–48 In the case of cucurbit[7]uril (Q[7]) we have shown that its encapsulation of the dinuclear platinum complex trans-[{PtCl(NH3)}2μ-dpzm]2+ (di-Pt, Fig. 1) slows the platinum complex's rate of reaction with guanosine, without affecting its normal DNA binding mode or its in vitro cytotoxicity.39 In contrast, other researchers have shown that the encapsulation of oxaliplatin with Q[7] reduced the drugs reactivity to both guanosine and methionine, but that in vitro cytotoxicity was also reduced.49
In this study, we extend our previous preliminary report of the encapsulation of di-Pt by Q[7].39 We have studied encapsulation by Q[7] and Q[8] of cisplatin, di-Pt and the related trinuclear complex trans-[trans-{PtCl(NH3)2}2—trans-{Pt(dpzm)2(NH3)2}]4+ (tri-Pt) (see Fig. 1). These were studied by NMR spectroscopy and molecular modelling in an effort to achieve a more detailed understanding of the relationship of the host to the guest in a potential protective drug delivery vehicle role.
![]() | ||
Fig. 2 1H NMR spectra showing (A) Q[7] and (B) Q[7] with added cisplatin at R = 1 in D2O at 25 °C. |
It is normal for an equilibrium to be established between the chloro- and aqua-forms of cisplatin when the platinum complex is dissolved in slightly acidic water (Fig. 3A), with Pt resonances for cis-[PtCl2(NH3)2] and cis-[PtCl(NH3)2(H2O)]+ being observed at −2160 and −1854 ppm respectively, consistent with literature values.55 Both of these forms of cisplatin can associate with Q[7]. Upon addition of Q[7] a second resonance is observed in the region of the chloro form at −2109 ppm, while the resonance due to the aqua form has significantly shifted to −1890 ppm (see Fig. 3B). A single resonance for the aqua form may suggest quantitative binding to Q[7] with slow exchange kinetics, or more likely, binding with fast to intermediate exchange (on the 195Pt NMR time scale). More significantly, the observation of separate resonances for free and bound chloro forms indicates slow exchange kinetics, suggesting that a fraction of the chloro form of cisplatin binds inside Q[7]. Encapsulation of cisplatin by Q[7] is consistent with the reported crystal structure of the metal complex cis-[SnCl4(OH2)2] encapsulated by Q[7].45 Whereas, the cis-[PtCl(NH3)2(H2O)]+ complex would be expected to bind only to the portal of Q[7], where it can maximise the electrostatic interactions and possibly form hydrogen bonds.
![]() | ||
Fig. 3 195Pt NMR spectra showing (A) cisplatin and (B) cisplatin with added Q[7] at R = 1 in D2O at 25 °C. |
Chemical shift (ppm) | |||||
---|---|---|---|---|---|
Complex | H5 | H5* | H3 | H3* | –CH2– |
a = Not applicable. | |||||
di-Pt–Q[7] | 6.29 (−1.49) | a | 7.37 (−0.37) | a | 2.94 (−0.88) |
di-Pt–[Q8] | 6.84 (−0.94) | a | 7.28 (−0.46) | a | 3.06 (−0.76) |
tri-Pt–Q[7] | 6.32 (−1.54) | 6.48 (−1.36) | 7.30 (−0.53) | 7.71 (−0.08) | 3.02 (−0.84) |
tri-Pt–Q[8] | 6.84 (−1.02) | 7.05 (−0.79) | 7.23 (−0.60) | 7.44 (−0.35) | 3.12 (−0.74) |
![]() | ||
Fig. 4 1H NMR spectra showing (A) di-Pt and (B) di-Pt with added Q[7] at R = 1 and (C) di-Pt with added Q[8] at R = 1 in D2O at 25 °C. |
As separate resonances for the free and Q[7]-encapsulated di-Pt were observed at R > 1 (results not shown), it is concluded that the metal complex binds with slow exchange kinetics on the NMR time scale.
The resonances from the Q[8]-bound di-Pt (Fig. 4C) were assigned using molecular modelling and depth profiling. Models of di-Pt encapsulated in Q[8] indicated that that the distances from the H3 and H5 protons to the dpzm methylene protons were very similar, and hence assignments could not be obtained from a NOESY spectrum. However, changes in the chemical shifts of the resonances from di-Pt suggested Q[8]-encapsulation was again centred on the dpzm linker rather than the platinum centres. Consequently, the H3, which is closer to the platinum centre, will be located less deeply in the Q[8] cavity, regardless of the pyrazolyl–methylene torsion angles. Therefore, the upfield resonance (6.64 ppm) is again assigned to the H5, with downfield resonance at 7.28 ppm being assigned to the H3.
Encapsulation of di-Pt by Q[8] induced large upfield shifts of the dpzm resonances (see Fig. 4C), with the di-Pt H3 and methylene resonances shifting by a similar amount to that observed for Q[7]-encapsulation; however, the H5 resonance shifted upfield by only 0.94 ppm compared to 1.49 ppm for Q[7]-encapsulation. This indicates that the platinum complex is positioned, on average, differently in Q[8] than in Q[7]. In addition, the resonance due to the remaining unexchanged (with the D2O) ammine protons of di-Pt shifted downfield upon Q[7]-encapsulation and upfield upon Q[8]-encapsulation. This suggests that the ammine protons are located on average deeper into the portal opening of Q[8], but outside and near the portal of Q[7]. Although it can not be clearly seen in Fig. 4, the dpzm resonances of the Q[8]-encapsulated di-Pt are significantly broader than was observed for Q[7]-encapsulation, e.g. the width at half-height of the H3 resonance is 2.5 Hz and 9.7 Hz for Q[7]- and Q[8]-encapsulation respectively. This suggests that the exchange rate between the Q[8]-encapsulated di-Pt and the free metal complex is faster than for Q[7]-encapsulation, consistent with the increased portal size.
The 1H NMR spectrum for the hydrolysed-form of di-Pt and the hydrolysed-form of di-Pt with added Q[7] as a function of time after mixing is shown in Fig. 5. Prior to encapsulation with Q[7], complete hydrolysis of di-Pt was confirmed by 195Pt NMR. The Pt resonance of di-Pt at −2327 ppm was absent and a resonance for the aqua complex observed at −2042 ppm. As expected, large upfield shifts of the resonances in the 1H NMR spectra are observed for the dpzm resonances, indicating the hydrolysed di-Pt is also encapsulated by Q[7]; however, almost 24 hours are required for all the platinum complex to be encapsulated. Whereas, di-Pt (Cl form) is rapidly encapsulated by Q[7] (less than the time required for mixing and accumulation of the 1H NMR spectrum). This indicates that it is considerably more difficult for the +2 platinum centre obtained upon hydrolysis of di-Pt to pass through the Q[7] portal.
![]() | ||
Fig. 5 1H NMR spectra showing (A) the hydrolysed form of di-Pt and with added Q[7] (B) 30 min, (C) 8 hours and (D) 15 hours after mixing. |
![]() | ||
Fig. 6 1H NMR spectra showing (A) tri-Pt and (B) tri-Pt with added Q[7] at R = 0.5 and (C) tri-Pt with added Q[8] at R = 0.5 in D2O at 25 °C. |
Fig. 7 shows the 1H NMR spectrum of the hydrolysed tri-Pt (confirmed by 195Pt NMR) and the metal complex with added Q[7] at R > 1 (i.e. excess metal complex). In addition to the resonances observed for the free tri-Pt–aqua, small peaks are seen for the Q[7]-encapsulated tri-Pt–aqua. One set of tri-Pt–aqua H5/H5* and H3/H3* resonances (6.30, 6.32, 7.38, 7.40 ppm) are shifted upfield, while the other H5/H5* and H3/H3* set of resonances (7.74, 7.77, 7.86 and 7.90 ppm) do not shift or shift marginally downfield. The set of aromatic resonances that shift upfield is consistent with the respective atoms being positioned inside Q[7], and the protons from the set of resonances showing little or no downfield shifts being located outside Q[7]. This suggests that the limiting Q[7] only encapsulates one of the two dpzm ligands of tri-Pt–aqua, and, as the resonances are in the slow exchange regime, the results indicate that Q[7] can not pass easily over the central dicationic platinum centre.
![]() | ||
Fig. 7 1H NMR spectra showing (A) the hydrolysed form of tri-Pt and with added Q[7] at (B) R = 7.5 and (C) R = 2.5. |
![]() | ||
Fig. 8 Molecular model of di-Pt encapsulated in (A) Q[7] and (B) Q[8] generated using HyperChem. The platinum complex was inserted into the cucurbituril in a variety of different starting positions. Energy minimisation of the encapsulated-di-Pt was then carried out to convergence. |
The binding model of tri-Pt by two Q[7] molecules (see Fig. 9) also suggested encapsulation centred on the dpzm bridging ligands, with the dpzm methylene and H5 protons located towards the centre, in terms of depth, but with the methylene protons again close to the cavity wall. The H3 protons are located inside Q[7], but more towards the portals than the corresponding H5, and the terminal ligands outside the portals. This conformation was consistent with the much larger upfield shift of the H5 resonances, compared to the H3 resonances observed in the 1H NMR experiments.
![]() | ||
Fig. 9 Molecular model of tri-Pt encapsulated in (A) Q[7] and (B) Q[8] generated using HyperChem. The platinum complex was inserted into the cucurbituril in a variety of different starting positions. Energy minimisation of the encapsulated-tri-Pt was then carried out to convergence. |
Optimised models suggested that Q[8] also preferentially encapsulated tri-Pt over the dpzm ligands (see Fig. 9); however, the smaller upfield shift of the H5/H5* resonances and the slightly larger upfield shift of the H3/H3* resonances upon Q[8]-encapsulation suggested a different binding conformation for Q[8]. Optimising the Q[8]-encapsulated tri-Pt geometries from different starting positions revealed energy minima that were shallower and higher relative to the global minimum than those for encapsulation by Q[7]. These minima included encapsulation of the central or terminal platinum centres, which could be accommodated, along with the ammine ligands, inside Q[8], although these conformations produced a local minima rather than the global minimum. Alternatively, when the Q[8] was centrally positioned over each dpzm, a minimised conformation could be achieved that accounted for the increased shielding of H3 and reduced shielding for the H5, compared to the Q[7]-encapsulation model, observed in the 1H NMR spectra. The two Q[8]s are in a similar orientation but not aligned, possibly to reduce electrostatic repulsion between the portals. As a result the central platinum was at an angle to the portal of each Q[8] that allowed it to project an ammine ligand into each portal, which may have also reduced effective inter-Q[8] portal–portal repulsion, because the ammine ligands carried some of the positive charge. This angle also oriented both pyrazolyls joined to the central platinum such that each N1 imido proton (H1) projected out of each Q[8] cavity towards the portal of the other Q[8], enabling an additional electrostatic attraction, as the H1 also carried some of the positive charge. H1 and H5 are bound to adjacent atoms of the pyrazolyl ring, so such an attraction would oppose deeper H5 encapsulation and account for the lower upfield shift observed when encapsulated by Q[7]. The two terminal platinum centres of tri-Pt minimised to conformations with the pyrazolyl rings rotated further around the methylene bonds for a more compact form with the Pt centres and terminal ligands rotated towards the cavity and the H5 rotated slightly towards the portal. This dpzm-encapsulated conformation allowed the Q[8]s to come close enough to each other to encapsulate all four dpzm H3 protons of tri-Pt, and therefore better reflected the observed changes in the proton chemical shifts.
The well established anticancer drug cisplatin was initially investigated for encapsulation within Q[7]. Cisplatin as a neutral complex has two possible binding modes available with any cucurbituril, either cavity or portal binding. Portal binding can occur through stabilisation by electrostatic interactions and hydrogen-bonding between the cucurbituril oxygens and the cisplatin ammine protons. The 1H NMR results indicated that at least some of the cisplatin bound with medium to fast exchange kinetics, while the 195Pt NMR indicated slow exchange kinetics (195Pt NMR time scale). These results suggested that some cisplatin was fully encapsulated within the cucurbituril cavity, with the remaining cisplatin presumably binding weakly at the portal. The cavity bound cisplatin is consistent with results obtained with other small neutral metal complexes, e.g.cis-[SnCl4(H2O)2] which has been shown by X-ray crystallography to be completely encapsulated within Q[7].45 In addition, the NMR data suggest that cis-[PtCl(NH3)2(H2O)]+ only binds Q[7] at the portals, consistent with the hydrophobic nature of the cucurbituril cavity.
Unlike cisplatin, the multinuclear platinum complexes bound quantitatively. Previously we reported, di-Pt binds Q[7] with slow exchange kinetics with the dpzm ligand being positioned within the cucurbituril cavity.39 Here we have extended the study to include the binding of di-Pt to the larger Q[8] and tri-Pt binding with both Q[7] and Q[8]. The resonances from di-Pt were significantly broader for encapsulation by Q[8], compared to Q[7]. This indicates that the rate of exchange between the encapsulated and free form is faster with the larger cucurbituril, and is consistent with the larger portal of Q[8] compared to Q[7]. Importantly, this result indicates that the rate of release of a multinuclear platinum complex can be modulated by the size of the cucurbituril. This could allow the balance between toxicity and cytotoxicity to be controlled, as slower release could reduce both toxicity and cytotoxicity. As expected, tri-Pt was encapsulated by Q[7] or Q[8] in a 1 : 2 ratio, with the kinetics again being slower for Q[7] than Q[8].
Another important difference between Q[8] and Q[7] encapsulation is the effect of the larger cavity size on the orientation of the pyrazolyl rings of the platinum complex and their relative relationship. Molecular modelling suggests that the torsion angles between the pyrazolyl rings in the dpzm ligand of di-Pt are significantly altered for Q[8] binding. The freedom of rotation about the C–C bonds of the CH2 bridging group is increased in the larger cavity and as a consequence the platinum centres are retracted into the portals. The distances between the metal centres, for minimised geometry, are ∼10.1 and ∼8.7 Å for Q[7] and Q[8] respectively. This is consistent with the 1H NMR results, where the ammine resonance shifted upfield upon Q[8] encapsulation but downfield with Q[7]. The retraction of the platinum centres into the portals could result in their greater protection from nucleophilic plasma and thiol containing proteins. Furthermore, given that the minimum possible distance between the Pt–Pt centres in vacuo is 6.6 Å, further protection could be possible with even larger Q cavities e.g. Q[9] or Q[10].40 Similar reductions in the distances between Pt–Pt centres were also found for the tri-Pt complexes.
Q[7] was shown to encapsulate the hydrolysed form of di-Pt, and based upon the similarity of the chemical shifts of the bound metal complex, it can be concluded that the cucurbituril was positioned in a similar fashion to the Cl form of di-Pt. However, of greater interest was the slower rate of encapsulation of the aqua form of di-Pt compared to the Cl form. This could be expected, given the energy cost of the +2 charge of a platinum centre passing through an electronegative cucurbituril portal to effect encapsulation of the linking dpzm ligands. Although the hydrolysed form of platinum anticancer drugs are more toxic than the corresponding Cl form, the very slow association/dissociation rates could result in a large decrease in toxicity, as the platinum complex would be released more slowly. While we have no data to support this possibility, the results with the aqua form of the di-Pt again highlight the potential of cucurbiturils as a platinum drug delivery system.
Footnotes |
† Electronic supplementary information (ESI) available: Colour versions of Fig. 8 and 9. See DOI: 10.1039/b513197a |
‡ Current address: School of Science, Food and Horticulture, University of Western Sydney, Campbelltown, NSW, 2560, Australia. |
This journal is © The Royal Society of Chemistry 2006 |